NCODA’s PQI simplifies the use of Darolutamide with Docetaxel for mHSPC
NCODA (National Community Oncology Dispensing Association) shared a post on LinkedIn:
“Prostate cancer remains the second most common cancer in U.S. men, with metastatic hormone-sensitive prostate cancer (mHSPC) requiring nuanced treatment. Darolutamide with docetaxel offers a vital option and NCODA’s PQI on this treatment simplifies its use by breaking down complex details into actionable steps.
In a recent interview, NCODA member Stephanie Parker, PharmD with Illinois CancerCare Care, provides insight into how the PQI supports her care team in delivering personalized, effective care, as well as clinical pearls like managing drug interactions, preventing docetaxel-related reactions and side effects monitoring.
Stephanie is a participant in the Darolutamide in Combination with Docetaxel for Metastatic Hormone Sensitive Prostate Cancer PQI in Action article.
Read the complete article here.”
Proceed to the video attached to the post.
More posts featuring NCODA.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023